ReviewClinical and experimental hepatology2020
Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2020.
Review in Clinical and experimental hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Treatment of hepatitis C in children and adolescents: our experience to date, current status, and prospects.Clinical and experimental hepatology · 2026Review
- Potential Drug Interactions in Psychiatric Patients Undergoing Pangenotypic Therapy for Hepatitis C Virus Infection.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Response to therapy with direct antiviral drugs in HCV-infected patients with diabetes.Scientific reports · 2025Article
- Loss to follow-up of patients after antiviral treatment as an additional barrier to HCV elimination.BMC medicine · 2024Article
- Real-world experience with direct-acting antiviral therapy in HCV-infected patients with cirrhosis and esophageal varices.Pharmacological reports : PR · 2024Article
- Treatment of HCV infection in patients with steatotic liver disease.Clinical and experimental hepatology · 2024Article
- Real-world effectiveness of genotype-specific and pangenotypic direct-acting antivirals in HCV-infected patients with renal failure.Clinical and experimental hepatology · 2023Article
- Real-World Efficacy and Safety of an 8-Week Glecaprevir/Pibrentasvir Regimen in Children and Adolescents with Chronic Hepatitis C-Results of a Multicenter EpiTer-2 Study.Journal of clinical medicine · 2023Article
- Pangenotypic tripleClinical and experimental hepatology · 2023Article
- Polymorphisms Related to Iron Homeostasis Associate with Liver Disease in Chronic Hepatitis C.Viruses · 2023Article
- Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era.World journal of gastroenterology · 2023Article
- Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens.Viruses · 2023Article
- Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients.World journal of gastroenterology · 2022Observational
- Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection.Journal of clinical medicine · 2022Article
- Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?Viruses · 2022Observational
- Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics.Journal of clinical medicine · 2021Article
- Article
- Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study.Annals of gastroenterology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recommendations set out the principles of diagnosis and treatment of hepatitis C virus (HCV) infections according to the most recent knowledge. The main goal of therapy for HCV infection is to eliminate the virus from the body, which consequently leads to arrest of progress or regression of changes in the liver. Current version of the recommendations prioritise pangenotypic regimens and provide guidelines in special populations of patients, such as children, cirrhotics, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) coinfected, those with renal failure, hepatic decompensation and non-responders to previous therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.